



Formula: C₂₀H₂₁F₃N₄O

MW: 390.41

CAS: 167933-07-5

MDL NUMBER: MFCD00918402

Smiles: FC(F)(F)c1ccc(cc1)N1CCN(CCn2c(=O)[nH]c3ccccc23)CC1

THERAPEUTIC CATEGORY: Flibanserin (code name BIMT-17; proposed trade name Girosa) is a drug that is currently being investigated by Boehringer Ingelheim as a novel, non-hormonal treatment for pre-menopausal women with Hypoactive Sexual Desire Disorder (HSDD).[1][2] HSDD is the most commonly reported female sexual complaint and characterized by a decrease in sexual desire that causes marked personal distress and/or personal difficulties. According to prevalence studies about 1 in 10 women reported low sexual desire with associated distress, which may be HSDD.[3] The neurobiological pathway of female sexual desire involves interactions among multiple neurotransmitters, sex hormones and various psychosocial factors. Sexual desire is modulated in distinct brain areas by a balance between inhibitory and excitatory neurotransmitters, serotonin acting as an inhibitor while dopamine and norepinephrine act as a stimulator of sexual desire.[4][5] Flibanserin is a 5-HT_{1A} receptor agonist and 5-HT_{2A} receptor antagonist that had initially been investigated as an antidepressant.[6][7] Preclinical evidence suggests that flibanserin targets these receptors preferentially in selective brain areas and helps to restore a balance between these inhibitory and excitatory effects.[5][8] HSDD has been recognized as a distinct sexual function disorder for more than 30 years.[9]

ACCEPTORS: 1

DONORS: 1

ROTATION BONDS: 2

N+O: 5

Chiral Centers: 0

LogP: 4.7

LogS: -5.03

LIPINSKI: 4

Synonyms: Flibanserin;Bimt

17;3-[2-[4-[4-(Trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one

CAS:167933-07-5

MF:C20H21F3N4O

MW:390.4

EINECS:

Product Categories: Flibanserin Flibanserin

Usage And Synthesis: Flibanserin

